Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence

被引:13
作者
Knight, Emmanuel M. [1 ]
Schiller, Daryl S. [1 ]
Fulman, Magda K. [1 ]
Rastogi, Rupangi [1 ]
机构
[1] Montefiore Nyack Hosp, Dept Pharm Serv, 160 North Midland Ave, Nyack, NY 10960 USA
关键词
Clostridium difficile; vancomycin; prophylaxis; recurrent; infectious diseases; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; HEALTH-CARE EPIDEMIOLOGY; RESISTANT ENTEROCOCCI; AMERICA; UPDATE; RISK; ADULTS; STRAIN;
D O I
10.1177/0897190019825994
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Limited evidence suggests that prophylactic oral vancomycin may be beneficial in preventing Clostridium difficile infection (CDI) recurrence, but long-term efficacy is unknown. Objective: To evaluate the long-term efficacy of oral vancomycin prophylaxis (OVP) in preventing CDI recurrence in subjects who require subsequent antibiotic exposure. Methods: A retrospective cohort study was conducted at a community hospital. A total of 91 subjects with a history of CDI between January 2013 and December 2015 who had a subsequent hospitalization requiring systemic antibiotics within 12 months were evaluated. Thirtytwo subjects who received prophylaxis with oral vancomycin were compared to 59 subjects who did not receive prophylaxis. Results: CDI recurrence within 12 months was significantly lower in subjects receiving OVP compared to those who did not receive OVP (6.3% vs 28.8%; odds ratio [OR]: 0.16; 95% confidence interval [CI]: 0.04-0.77; P = .011) including patients whose previous CDI was an initial episode (3.7% [1/27] vs 28.3% [15/53]; OR: 10.3; 95% CI: 1.28-82.6; P = .009). Conclusion: Use of OVP in subjects with a history of CDI up to 12 months prior to subsequent antibiotic exposure appears to reduce the risk of CDI recurrence for up to 12 months.
引用
收藏
页码:633 / 639
页数:7
相关论文
共 31 条
[1]   Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review [J].
Abou Chakra, Claire Nour ;
Pepin, Jacques ;
Sirard, Stephanie ;
Valiquette, Louis .
PLOS ONE, 2014, 9 (06)
[2]   Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease [J].
Al-Nassir, Wafa N. ;
Sethi, Ajay K. ;
Li, Yuejin ;
Pultz, Michael J. ;
Riggs, Michelle M. ;
Donskey, Curtis J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2403-2406
[3]   Narrative review: The new epidemic of clostridium difficile-associated enteric disease [J].
Bartlett, John G. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :758-764
[4]   Risk factors for Clostridium difficile infection [J].
Bignardi, GE .
JOURNAL OF HOSPITAL INFECTION, 1998, 40 (01) :1-15
[5]   Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection [J].
Brown, Kevin A. ;
Khanafer, Nagham ;
Daneman, Nick ;
Fisman, David N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) :2326-2332
[6]  
Butler M., 2016, EARLY DIAGNOSIS PREV
[7]   Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections [J].
Carignan, Alex ;
Poulin, Sebastien ;
Martin, Philippe ;
labbe, Annie-Claude ;
Valiquette, Louis ;
Al-Bachari, Hamed ;
Montpetit, Louis-Philippe ;
Pepin, Jacques .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (12) :1834-1840
[8]   Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence? [J].
Chapin, Ryan W. ;
Lee, Tiffany ;
McCoy, Christopher ;
Alonso, Carolyn D. ;
Mahoney, Monica V. .
ANNALS OF PHARMACOTHERAPY, 2017, 51 (09) :804-810
[9]   Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [J].
Cohen, Stuart H. ;
Gerding, Dale N. ;
Johnson, Stuart ;
Kelly, Ciaran P. ;
Loo, Vivian G. ;
McDonald, L. Clifford ;
Pepin, Jacques ;
Wilcox, Mark H. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (05) :431-455
[10]   Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice [J].
Deshpande, Abhishek ;
Hurless, Kelly ;
Cadnum, Jennifer L. ;
Chesnel, Laurent ;
Gao, Lihong ;
Chan, Luisa ;
Kundrapu, Sirisha ;
Polinkovsky, Alexander ;
Donskey, Curtis J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) :3988-3993